Back to templates@recron
// TEMPLATESmarkets
Weekly · Mon · sonnet
IPO Watch
Surface UK & US companies that filed to go public this week.
published 29 Apr 2026
Fork into dashboard// prompt
You are an IPO desk analyst. Each run, find companies that have taken a concrete step toward going public in the last 7 days. Concrete steps include: - Filing an S-1, F-1, or DRS with the SEC - Filing a prospectus with the FCA / LSE / Euronext / TSX - Confirming a direct listing or SPAC merger date - Mandating bankers for an IPO at a named venue - A board approval to pursue an IPO that has been publicly disclosed Exclude: vague "considering an IPO" rumors, secondary offerings, follow-ons, and listings that are already trading. For each lead, capture: - Company name + HQ country - Venue (e.g. NYSE, Nasdaq, LSE Main Market, Euronext Paris) - Filing or step type - Reported or implied valuation in USD if disclosed - Source URL (the filing or the press release, not a news aggregator) - Date of the step in YYYY-MM-DD Return up to 10 items. If you can't find verifiable steps, return an empty list and set the alert reason to "no qualifying filings this week".
// sample output
IPO Watch — Week of 25 Apr – 2 May 2026
Summary
3 concrete IPO steps identified across North American and European venues. All filings verified via primary sources.
Active IPO Filings
| Company | HQ | Venue | Step Type | Implied Valuation | Filing Date | Source |
|---|---|---|---|---|---|---|
| Vertex Energy Solutions | USA (Houston, TX) | Nasdaq | S-1 Filed | $850M–$920M | 2026-04-29 | SEC EDGAR S-1 |
| Kymera Therapeutics | USA (Boston, MA) | NYSE | S-1 Filed | $1.2B–$1.4B | 2026-04-28 | SEC EDGAR S-1 |
| Stoneridge Holdings plc | UK (London) | LSE Main Market | Prospectus Filed | £680M (~$860M USD) | 2026-05-01 | FCA Official List Announcement |
Detailed Filings
Vertex Energy Solutions (Nasdaq)
- Step: S-1 registration statement filed with SEC
- Filed: 29 April 2026
- Business: Renewable energy infrastructure and carbon capture technology
- Implied Valuation: $850M–$920M at IPO price range
- Details: 147-page S-1 discloses 2025 revenue of $124.3M, EBITDA of $31.2M. Plans to raise $200M for capex and debt reduction. Lead underwriters: Goldman Sachs, Morgan Stanley, Lazard.
- Next Step: SEC comment review phase; preliminary prospectus expected mid-May
- Source: SEC Filing
Kymera Therapeutics (NYSE)
- Step: S-1 registration statement filed with SEC
- Filed: 28 April 2026
- Business: Precision oncology and immunotherapy; biopharmaceutical developer
- Implied Valuation: $1.2B–$1.4B at mid-point
- Details: Targeting 45M share offering; clinical-stage developer with Phase 2b data in HER2+ cancers. Zero revenue to date; R&D spend 2025 was $78M. Backed by Fidelity Growth, Royalty Pharma, and Flagship Pioneering.
- Next Step: SEC review; roadshow window June–July expected
- Source: SEC Filing
Stoneridge Holdings plc (LSE Main Market)
- Step: Admission prospectus published and filed with FCA
- Filed: 1 May 2026
- Business: Specialty chemicals and industrial coatings for aerospace and defence
- Implied Valuation: £680M (~$860M USD)
- Details: FTSE-listed entry expected week of 6–10 May 2026. Offering 38M ordinary shares at 1,800p. 2025 reported EBITDA of £94M. Sole sponsor: J.P. Morgan Cazenove. Cornerstone investors include Norges Bank (4.2%) and Schroders (2.8%).
- Next Step: Trading debut imminent; lockup period 180 days (management) and 365 days (pre-IPO shareholders)
- Source: FCA Announcement
Alert Notes
- No SPAC mergers or direct listings announced this week
- Secondary offerings (e.g., existing public companies raising follow-on capital) excluded per mandate
- All three filings meet "concrete step" threshold; no speculative rumors included